In conversation with... Janet Brown

from Listen to The Lancet Oncology · host The Lancet

Prof Janet Brown (University of Sheffield, Sheffield, UK) discusses the phase 2/3 STAR trial on treatment cessation versus continuation with tyrosine kinase inhibitors in advanced renal cell carcinoma.

Episode metadata supplied by the publisher feed · Published Mar 1, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

In conversation with... Janet Brown

0:00 20:43

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Oncology?

This episode is 20 minutes long.

When was this Listen to The Lancet Oncology episode published?

This episode was published on March 1, 2023.

Can I download this Listen to The Lancet Oncology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!